Abigail
@loamfeet.bsky.social
Reposted by Abigail
The extraordinary endTB trial offers a path to much shorter and less toxic curative therapy for drug resistant tuberculosis. This is huge news. Hopefully we'll see these regimens adopted quickly, especially now that bedaquiline is more affordable.
So grateful to all the researchers involved.
So grateful to all the researchers involved.
Proud to see the endTB trial, work of a huge team, led by @partnersinhealth.bsky.social, @msf.org, IRD & supported by @unitaid.bsky.social, published in @nejm.org today. Safe, effective, shortened treatments for drug-resistant TB can be available to all. #TBSky #ForeignAid tinyurl.com/NEJM-endTB
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis | NEJM
For decades, poor treatment options and low-quality evidence plagued care for patients
with rifampin-resistant tuberculosis. The advent of new drugs to treat tuberculosis
and enhanced funding now p...
tinyurl.com
January 30, 2025 at 8:38 PM
The extraordinary endTB trial offers a path to much shorter and less toxic curative therapy for drug resistant tuberculosis. This is huge news. Hopefully we'll see these regimens adopted quickly, especially now that bedaquiline is more affordable.
So grateful to all the researchers involved.
So grateful to all the researchers involved.